merged_340b-apexus-drugs-middleman.txt
<question_number>1</question_number>
<answer>$2,500</answer>
<other>The article states that Virginia King got a bill for over $2,500 from the first hospital, and her responsibility was "nothing" at the second clinic.</other>

<question_number>2</question_number>
<answer>7 years</answer>
<other>The article states Apexus "was established as a small nonprofit in 2007 but became a for-profit company in 2014." From 2007 to 2014 is 7 years.</other>

<question_number>3</question_number>
<answer>N/A</answer>
<other>The article mentions Baxter approached regulators in 2021, not 2019.</other>

<question_number>4</question_number>
<answer>N/A</answer>
<other>While the article mentions that Acentrus "resulted in an additional $20 million" in revenue within the 340B program, it doesn't provide this as a percentage of Apexus' total revenue.</other>

<question_number>5</question_number>
<answer>85 percent</answer>
<other>The article states: "Hospitals that participated in the program billed the state health plan far more than hospitals that did not -- almost 85 percent more for certain cancer drugs."</other>

<question_number>6</question_number>
<answer>about a month</answer>
<other>The article states: "For about a month afterward, regulators reviewed any communication Apexus had with health care facilities to make sure the company didn't overstep"</other>

<question_number>7</question_number>
<answer>2</answer>
<other>The article mentions two complaints: one filed in 2021 and another in 2022.</other>

<question_number>8</question_number>
<answer>N/A</answer>
<other>The article doesn't provide information about what percentage of the original safety-net providers remained in the program by 2023.</other>

<question_number>9</question_number>
<answer>N/A</answer>
<other>While the article mentions Apexus advised hospitals they "can mine records as far back as 36 months for eligible patients," it doesn't specifically state how many months Christus St. Vincent reviewed.</other>

<question_number>10</question_number>
<answer>N/A</answer>
<other>The article mentions that "Apexus employees received bonuses if the company increased its revenue each year" but doesn't specify a minimum threshold.</other>

<question_number>11</question_number>
<answer>Christus St. Vincent</answer>
<other>The article describes how Virginia King's bill from Christus St. Vincent was sent to collections in July, and after The Times inquired, the hospital claimed it was "a misunderstanding and has been resolved."</other>

<question_number>12</question_number>
<answer>$227 million</answer>
<other>The article states: "Apexus was on track to double its revenue from 2018 to 2022, projecting $227 million that year"</other>

<question_number>13</question_number>
<answer>Apexus</answer>
<other>The article describes Apexus as holding "340B University" events and also earning "millions of dollars on drug purchases made outside the 340B program"</other>

<question_number>14</question_number>
<answer>Apexus</answer>
<other>The article mentions that Apexus employees were described as "sales-type" in a complaint, and also states that "Apexus has advised hospitals that they can mine records as far back as 36 months for eligible patients"</other>

<question_number>15</question_number>
<answer>2014</answer>
<other>The article states Apexus "became a for-profit company in 2014" and "Around the same time, 340B began to explode for a number of reasons."</other>

<question_number>16</question_number>
<answer>Premier</answer>
<other>The article states: "In early November, Premier, the main competitor to Apexus's parent company, Vizient, sued the federal government over these sales."</other>

<question_number>17</question_number>
<answer>Marsha Simon</answer>
<other>The article identifies Marsha Simon as someone "who as a staff member of a congressional committee helped write the bill that authorized the program" and later criticized aspects of its implementation.</other>

<question_number>18</question_number>
<answer>free-standing oncology clinic</answer>
<other>The article states: "Mrs. King switched to a free-standing oncology clinic that does not qualify for the federal drug program."</other>

<question_number>19</question_number>
<answer>more than 200 percent</answer>
<other>The article states that New York changed its Medicaid administration "in part because the state had discovered the cost of the federal program had increased by more than 200 percent over three years"</other>

<question_number>20</question_number>
<answer>Acentrus</answer>
<other>The article describes Acentrus as a business that "helped hospitals and clinics provide data to manufacturers in exchange for deeper discounts and access to those drugs" and notes it "was sold last year."</other>